Immunome Inc
Contact Information
Company Details
Location Type: Headquarters
Industry: Pharmaceutical Preparations
Ownership: Private
Year Founded: 2006
Sales Range: $1,000,000 to $4,999,999
Employees: 1 to 5
Is This Your Customer, Supplier, Or Partner?
Is This Your Business?
Is This Your Customer, Supplier, Or Partner?
Pull Their Credit Report CREATE A FREE ACCOUNT
Company Credit Alerts
Recent Alerts
Credit Risk Increase
No
Overall Payments
No
Peer Payments
No
Bankruptcy
No
Tax Liens
No
UCC Filings
No
See All Credit Alerts On Your Customers From The Past 12 Months
Company News
Latest News
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Business Wire Health News
Feb 6 2024
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Business Wire Health News
Jan 8 2024
Immunome to buy assets from California biotech company
The Puget Sound Business Journal
Dec 29 2023
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
Business Wire Professional Services News
Jun 29 2023
Immunome and Morphimmune enter merger and a $125M private placement
Seeking Alpha Mergers
Jun 29 2023
Analyze Your Entire AR Portfolio with One Free Credit Tool
LEARN MORECompany Buying Behavior
Overall Company Spend
Credit Analysis Tip
Purchases of key products and services provides insight into whether a business is growing or declining financially. Analyzing spending enables creditors predict risk scenarios before other credit analysis methods. Lean how in our latest case study.
DOWNLOAD CASE STUDYCompany Credit Alerts
Recent Alerts
Credit Risk Increase
No
Overall Payments
No
Peer Payments
No
Bankruptcy
No
Tax Liens
No
UCC Filings
No
See All Credit Alerts On Your Customers From The Past 12 Months
Sales Insights
More Businesses Like this
Discover other companies in the same industry you can sell to: